Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to provide treatment with Ipilimumab to subjects who
have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who
have no alternative treatment options, and whose physicians believe, based upon available
data on benefit and risk, that it is appropriate to administer Ipilimumab at a dose of 3
mg/kg induction (with re-induction, if eligible), or for eligible subjects previously
enrolled in Ipilimumab studies CA184-042, CA184-078, CA184-087, MDX010-16, or MDX010-20.